TTX-564 is under clinical development by Trueline Therapeutics and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase I drugs for Myelodysplastic Syndrome have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TTX-564’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TTX-564 overview

TTX-564 is under development for the treatment of myelodysplastic syndrome and solid tumor. The therapeutic candidate is a bi-specific T cell engager that acts by targeting CD33 expressing tumor cells and CD3 expressed on T-cells. It is administered through subcutaneous route.

Trueline Therapeutics overview

Trueline Therapeutics, a subsidiary of Anji Pharmaceuticals Inc, is a biotechnology research company engaged in developing novel therapeutics for the treatment of cancer. The company is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of TTX-564’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.